EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 316 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Girl Whose Insides Were Sucked From Her Body While Sitting On... June 14, 2019 Open Enrollment for 2022 Affordable Care Act Plans is Here! November 1, 2021 High HPV Vaccination Coverage in England Associated with a Substantial Reduction... June 25, 2026 Mom Says Family Was Kicked Out Of Movie Theater Because Her... April 19, 2019 Load more HOT NEWS Navigating Cancer Survivorship as a Transgender or Non-Binary Person Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in... ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July Altering Diet Enhances Response to Cancer Treatments in Mice
